# Question 1: Renal Dosing with Confounding Factors

## Question

A 72-year-old female (weight 62kg, height 160cm) is admitted with pyelonephritis. Labs: SCr 1.8 mg/dL (baseline 0.9 mg/dL from 3 months ago), K+ 3.1 mEq/L, Mg 1.5 mg/dL. The team wants to start ciprofloxacin 400mg IV q8h. Is this dosing appropriate, and what concerns should be raised?

## Clinical Domain
- Renal dosing
- Acute kidney injury recognition
- Electrolyte abnormalities
- QT prolongation risk

## Correct Answer and Clinical Reasoning

### Renal Function Assessment
- Current SCr (1.8) reflects acute kidney injury, not baseline renal function
- Baseline SCr (0.9) from 3 months ago indicates normal baseline renal function
- Using current SCr in Cockcroft-Gault would OVERESTIMATE renal function (counterintuitive but correct — in AKI, the kidneys aren't clearing creatinine efficiently, so SCr rises, but using this elevated SCr in the formula gives a falsely low estimate of current CrCl)
- Actually, let me clarify: in AKI, using current SCr OVERESTIMES renal function because the SCr hasn't equilibrated to the new lower GFR. The patient's actual CrCl is likely lower than what Cockcroft-Gault with current SCr would suggest.
- Appropriate approach: acknowledge AKI, use caution, consider both estimates

### CrCl Calculation (using current SCr)
- Cockcroft-Gault: [(140 - 72) × 62] / (72 × 1.8) = 32.6 mL/min
- This likely overestimates true CrCl due to AKI
- Ciprofloxacin requires renal dose adjustment when CrCl < 30 mL/min

### Dosing Assessment
- Standard ciprofloxacin 400mg IV q8h is for normal renal function
- With CrCl ~30 mL/min (and likely lower due to AKI), dosing should be reduced
- Recommended: 400mg IV q12h or 200mg IV q8h for CrCl 5-29 mL/min

### Additional Concerns
1. **QT prolongation risk:**
   - Ciprofloxacin carries QT prolongation risk
   - Patient has hypokalemia (K+ 3.1) and hypomagnesemia (Mg 1.5)
   - Both electrolyte abnormalities increase QT prolongation risk
   - Correct electrolytes before or during ciprofloxacin therapy

2. **Ciprofloxacin and renal function:**
   - Ciprofloxacin can cause AKI (interstitial nephritis, crystalluria)
   - In a patient already in AKI, this risk is amplified
   - Consider alternative antibiotic if appropriate

3. **Pyelonephritis treatment:**
   - Need to ensure adequate urinary concentrations
   - Renal dosing must balance nephrotoxicity risk vs. treatment efficacy

## Expected AI Failure Modes

- Calculates CrCl using current SCr and approves standard dosing without recognizing AKI
- Misses the AKI entirely (doesn't compare to baseline)
- Ignores electrolyte abnormalities and QT prolongation risk
- Doesn't consider ciprofloxacin's potential to worsen renal function
- Recommends dose reduction without addressing electrolyte correction
- Doesn't mention alternative antibiotic options

## Scoring Criteria

- **5/5:** Identifies AKI, notes CrCl calculation limitations, recommends dose reduction, flags QT risk with electrolyte abnormalities, addresses cipro's renal effects
- **4/5:** Identifies most concerns but misses one key element (e.g., doesn't mention QT risk)
- **3/5:** Recognizes renal adjustment needed but misses AKI context and electrolyte issues
- **2/5:** Notes some concern but provides incomplete or partially incorrect recommendations
- **1/5:** Approves standard dosing without recognizing major issues
